BioSpace News Archive

Insightec, a global healthcare company dedicated to using acoustic energy to transform patient care, announced its launch of Exablate Prime, a significant enhancement to the Exablate Neuro platform.

Eilean Therapeutics LLC today announced the completion of a single ascending dose Phase 1 clinical study of lomonitinib and initiation of a multiple ascending dose Phase 1 program.

Phanes Therapeutics, Inc. announced that the U.S. Patent and Trademark Office has granted the registration of trademarks for its proprietary technology platforms PACbody®, SPECpair® and ATACCbody®.

Immunocore Holdings plc, announced its intention to offer, subject to market and other conditions, $300.0 million aggregate principal amount of convertible senior notes due 2030 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced, as required by Nasdaq Stock Market rules, the grant of inducement awards to five new employees.

Inotiv, Inc. announced that it will issue its financial results for the fiscal 2024 first quarter ended December 31, 2023, on Wednesday, February 7, 2024, after the close of the stock market.

Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the fourth quarter and full year 2023 after market close on Wednesday, February 14, 2024.

Mineralys Therapeutics, Inc. (NASDAQ: MLYS) today announced that Chief Executive Officer Jon Congleton will be participating in a fireside chat at the Guggenheim Securities 6th Annual Biotechnology Conference, being held in New York City on February 7-8, 2024.

DENTSPLY SIRONA Inc. announced that the Company will be hosting an investor conference call and live webcast on Thursday, February 29, 2024, at 8:30 am ET to review its fourth quarter and full year 2023 financial results.

Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that the company will release its financial results for the fourth quarter and full year ended December 31, 2023 after the market closes on Wednesday, February 21, 2024.